Drug nearly doubles survival in advanced pancreatic cancer, how daraxonrasib overcame an 'undruggable' disease

Article excerpt

A new drug called daraxonrasib has nearly doubled survival rates in advanced pancreatic cancer, a disease long considered nearly impossible to treat. For patients diagnosed with metastatic pancreatic cancer between 2015 and 2021, roughly 97% died within five years, a grim baseline that underscores the breakthrough's potential significance. The drug targets a previously 'undruggable' mutation, marking a rare win against one of cancer's deadliest forms. Researchers say the findings could reshape treatment for a disease that kills tens of thousands annually.